## C. GALEFFI (\*)

## Medicinal Plants. What's in this Name? (\*\*)

The isolation of the first acrive principles from medicinal plants pointed out the first distributionation between the empirie use, related to the bilistic idea of vegetal drugs, and the scientific one based on updated criteria. After 170 years it can be claimed that medicinal plants haven't as a sube destiny the isolation of acrive principles, but, on the other hand, it is municially us represent a subterior of the contraction of the contraction of the paper of modern medicine or almost as an alternative to it.

Some medicinal plants are utilized today for the isolation of important active principles (in competition with the total chemical synthesis) and these chemicals have the honour of the monographs in modern pharmacopoeias.

Other plants are used for the isolation of accumulation compounds or key products of biosynthesis which can be advanced steps in the synthesis of complex solichiral and policyclic molecules of pharmaceutical interest.

Moreover, where vagetal drugs, on account of their therapeutic value of efficiency and strey, ear, as such granted the benome to acceled to modern pharmacopocias with a defined constant of active principles (one or more, if everyone concurs in the same therapeutic anily detectable by transfard analytical method. The pharmacopocia monagraphs for these drugs also report the macro and microscopic description for their beastard identification, the limits for extraosoragans and elements. These data of bottorical and quals and quantitative chemical destification as well as the biological destification, the limits for extraosoteristic destination of the contraction of the contraction of the studies warmed for the formulations, are necessary for the registration of plane-based proprietary medicinal products and for plane-based orientical placenies.

However, only a few are the known plants which have scientifically sound data for chemical and pharmacotoxicological standardization to garantee quality,

(\*) Istituto Superiore di Sanità - Laboratorio di Chimica del Farmaco.

<sup>(\*\*\*)</sup> Presented at the International Congress on \* Medicinal Plants \* (Sansepolero (AR), 17-19 October - Roma, October 20th 1987), organized by the Accademia Nationale delle Scienze detta dei XI.

safety and efficacy in their formulations. Only fragmentary data of separate researchers are available since the pharmaceutical industry is not interested in

this area where it cannot protect the findings.

Many plants have value only for traditional use, and for them it is laberious and difficult to get the adversariational information, to relate the activity to something chemically definite, i.e., the active principles, the ignorance of which haupers their assurand presence in the derivative. In other words, the use of berhal drugs in primary lacalth care with the same standard of quality, efficacy and safety as for each parameterisal products take roughed by the WHO's ragional genetics for traditional medicine) is yet feasible for only a few of them, and this can be claimed in sharp disappresses with what is state in the resolution and this can be claimed in sharp disappresses with which state in the resolution proposal of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) and the company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up by the Company of the European Eralment (Dec. 182-21/185) drown up

Then let us consider the first requirement, that of safety, indispensable for the food use of a vegetal source, usually checked eventually by public institutions or appointed bodies. Many are the so-called medicinal plants which are utilized in food context and at any rate the food-drug discrimination does not fall within the frame of traditional medicine, as also Paracelsus wanted to theorize. Toxic agents naturally occur in foods, as the title of a famous text published by the U.S. National Academy of Sciences in 1966 stated, and as has been shown in acute administration for some plants. Thus there are plants which can deserve the qualification of safety (GRAS - generally recognized as safe), whereas for some of the over 500 seasonines of the Council of Europe a threshold limit has been established for the toxic ingredients, such as B-asarone, α» and β-thujones, santonin, hypericin, safrole, hydrocyanic compounds, quassin, Many other plants, or better herbal drugs, have the informal status of safety in the scientific community, at least till they are declared dangerous eventually, as has happened for Aristolochia clematitis, Symphytum officinale, Phytolocea americana, Tussilago farlara.

Of corres, if the food see has the prerequisite of harmlessness, the medical use should have the requisite of efficiency. Well, for more plans to different traditions only indications of all literature are available and they are not in agreement with uploader alone of pushbogy, physiology and therapy. However, the meetins of these indications on the preparation labels is not allowed by law in table and the preparation labels in not allowed by law in table and, the meaning of the preparation labels in not allowed by the preparation of the table and the product of the preparation of the product of the preparation of the product of

In the recent past, for these herbal preparations, unacceptable under the EEG directives on medicinal products, the possibility of a special registration with general indications for minor diseases or symptomatic relief had been envisaged. This point of view has been recently shared by the Ministry of Social Affairs and Family of France, which has instructed the manufacturers for the preparation of herbal products (about 19 berbal draps) with the deservation of good manufacturing pacticies, to be add in planumacie, with detailed indications (different for consumers and for doctors) always referring to traditional use. The same trend for these products called "Fullibre mechasises" is emerging in Canada. They would have a guarantee of safety and efficiency even thought not proven by standardized mechasia as for other medicinal products.

Thus, between the "drug use" and the "food use" the "traditional drug use" should be set up: it should be partially assimilable to the "over the counter" (OTC) products. Such proposals are related to the peculiar marketing condition in France, where this sale is actually permitted to pharmacies only. However, in French pharmacies herbal mixtures and their derivatives are on display, labeled, or even maned with infeatious which formanably have been

eliminated by suitable repressive action in Italy.

In Italy, and also in the U.S., as aforementioned, no reference to the activity can be added to these preparations (often mixtures lidigically sacrobled, reserved to self-aedication and to the private bealth sector) which the consumer holds but has no memory or written indication of their function. Some manafecturers, thus not being permitted to mention the product's activity, resort to the "absence of pestiddes" or some other claim to usality.

Finally the "herbalist" problem, i.e., marketing outside the pharmacy, is a further element to be considered. This is also referred to in the aforementioned resolution of the European Parliament, which however does not treat the following questions:

- Should the ethical herbal drugs be sold in herbal shops (not only in pharmacies) or only if hypodosed, with threshold limit to be established and enforced (and this is very difficult)?
- ii) Should plants of some relevant activity be sold without any reference to their standardization and without any guidance regarding combinations?
- iii) Should plants of restricted use, not mentioned in pharmacognosy text-books, be sold?

In spite of these dilemmas and inconsistencies, the empirical use of so-called medicinal plants is now being reproposed without consideration of the active principles which, even if their isolation is not required, have sooner or later qualified the true medicinal plants.